Scarica l'app Stockscreener
234.03
4.26%
9.56
Dopo l'orario di chiusura:
235.20
1.17
+0.50%
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - GlobeNewswire Inc.
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Securities Fraud Investigation Into Alnylam - GlobeNewswire
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% - Trefis
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - wboc.com
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire Inc.
An Alnylam (ALNY) officer proposes a $399K share sale that includes shares to cover an equity-award tax bill. - Stock Titan
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% - Simply Wall Street
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49% - simplywall.st
Alnylam Shares Fall as Investors Weigh Earlier 2026 Outlook Reset Against a Near-Term Data Wait - Quiver Quantitative
Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today - benzinga.com
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN) - The Globe and Mail
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Stock Forecast & Analyst Predictions - simplywall.st
Alnylam Pharmaceuticals (ALNY) Stock Forecast and Price Target 2026 $ALNY - MarketBeat
A former football player’s symptoms were attributed to football or aging. His heart diagnosis came late. - Stock Titan
AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM - Times Argus
Down 35% This Year, Alnylam Still Has Wall Street Calling 44% Upside - NAI500
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY) - Seeking Alpha
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - Yahoo Finance
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation - TradingView
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - Yahoo Finance
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. - The Motley Fool
Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com - Investing.com Nigeria
Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY) - Seeking Alpha
Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO - The Business Journals
The next Alnylam? RNAi biotech City Therapeutics files for IPO - Endpoints News
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Alnylam Pharmaceuticals (ALNY) Misses Q2 Earnings and Revenue Estimates - Eastern Progress
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with a 55% Upside Potential - DirectorsTalk Interviews
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook - Yahoo Finance
Will RNAi Market Growth Change Alnylam Stock's Narrative? - simplywall.st
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial - TradingView
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial - Yahoo Finance
Alnylam Pharmaceuticals, Inc. RNAi Roundtable Call Transcript - GuruFocus
Alnylam Pharmaceuticals (ALNY) Highlighted As An Oligonucleotide Therapeutics Leader Through 2035 - simplywall.st
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Gains Attention After Fresh RNAi Data, Is It 33% Undervalued? - simplywall.st
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $300 - Moomoo
Diluted earnings per share (diluted EPS) of Alnylam Pharmaceuticals, Inc – VIE:ALNY - TradingView
1.07%
2.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):